(UroToday.com) Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment and is usually achieved with luteinizing hormone-releasing hormone (LHRH) agonists or gonadotropin-releasing hormone (GnRH) antagonists. Relugolix is a first-in-class FDA-approved, oral, highly selective, GnRH receptor antagonist that is given once daily with an effective half-life of 25 hours for the treatment of adult men with advanced prostate cancer. In the phase 3 HERO study, relugolix demonstrated sustained testosterone suppression to castrate levels in 96.7% of men, superior to that of leuprolide, and a comparative 54% decrease in risk of major adverse cardiovascular events.1 The HERO study included men with a broad range of ages, with a median of 71 and a range from 47 to 97 years of age. Dr. Michael Cookson and colleagues at the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, Dr. Michael Cookson presented the results of their study further characterizing the impact of age on the use of relugolix in advanced prostate cancer from the HERO study.